ReviewFrontiers in pediatrics2025
Diagnostic value of combined detection of pepsinogen, gastrin-17, and
Review in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluated the diagnostic efficacy of combining pepsinogen (PG I/II), gastrin-17 (G-17), and Methods: Between June 2018 and August 2023, 65 children with chronic gastritis and 50 healthy controls participated. Inclusion criteria for both groups: Age 6-12 years, chronic gastritis confirmed by endoscopy and histopathology for the gastritis group, and absence of GI symptoms for the control group. Exclusion criteria: Severe cardiopulmonary dysfunction, gastroduodenal surgery, recent use of PPIs/antibiotics, and H. pylori eradication therapy. Serum levels of PG I, PG II, and G-17 were determined by ELISA, and 13C-UBT was used to detect Helicobacter pylori (Hp) infection. Results: Combined detection showed significantly higher positive rates than individual PG I/II or G-17 tests ( Conclusion: The combined detection of PG I/II, G-17, and 13C-UBT shows strong diagnostic potential for Helicobacter pylori-associated chronic gastritis in children, offering enhanced diagnostic accuracy and a non-invasive tool for early screening and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.